Alcobra's ADHD drug meets goals in late-stage study

[October 06, 2014]  (Reuters) - Alcobra Ltd said its drug to treat attention deficit disorder met the main goals of a late-stage trial, reducing the symptoms of the condition better than a sugar pill.

The study results were derived after the company excluded data from four patients who showed an extreme response to the placebo, Alcobra said in a statement.

The company said the study scored the drug, Metadoxine, on the same scale used in studies that evaluated other attention deficit hyperactivity disorder, or ADHD, drugs.

(Reporting by Vidya L Nathan in Bangalore; Editing by Savio D'Souza)

[© 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.